Karyopharm Secures $30 Million in Private Placement Financing

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Mar 24 2026

0mins

KPTI-3.28%

Should l Buy KPTI?

Source: PRnewswire

Financing Agreement: Karyopharm Therapeutics has entered into a securities purchase agreement with RA Capital Management, expected to yield approximately $30 million in gross proceeds, with potential total proceeds of about $44 million if accompanying warrants are fully exercised, enhancing the company's liquidity for future growth.
Share Sale Details: In this private placement, the company will sell 1,030,354 shares of common stock at $6.785 per share and 3,391,164 pre-funded warrants at $6.7849 each, with the transaction expected to close around March 26, 2026.
Planned Use of Funds: Karyopharm intends to utilize the proceeds from the private placement for general corporate purposes, including supporting ongoing and planned clinical trial activities, ensuring sufficient funding for the company's operational plans moving forward.
Market Compliance: The financing is priced at-the-market under Nasdaq rules, and the securities sold are not registered under the Securities Act of 1933, ensuring compliance while executing capital operations.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy KPTI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on KPTI

Wall Street analysts forecast KPTI stock price to rise

6 Analyst Rating

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 5.480

Low

6.00

Averages

13.83

High

21.00

Current: 5.480

Low

6.00

Averages

13.83

High

21.00

Piper Sandler

Overweight

downgrade

$12 -> $8

2026-03-30

New

Reason

Piper Sandler

Price Target

$12 -> $8

AI Analysis

2026-03-30

New

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Karyopharm to $8 from $12 and keeps an Overweight rating on the shares. Phase III SENTRY data in myelofibrosis met the first co-primary endpoint. However, it missed the second co-primary endpoint, the firm notes. Importantly, seli-rux showed a significant overall survival benefit with 4.7% deaths vs. 10.2% on ruxolitinib at about 12-month follow-up. Karyopharm plans to meet with FDA to discuss potential sNDA submission for seli-rux in myelofibrosis. While seli-rux miss on Abs-TSS introduces some uncertainty into the likelihood of approval in myelofibrosis, Piper believes the rapid and profound SVR-35 reduction coupled with the OS benefit could be used to gain approval.

Baird

Outperform -> NULL

downgrade

$21 -> $15

2026-03-25

Reason

Baird

Price Target

$21 -> $15

2026-03-25

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on Karyopharm to $15 from $21 and keeps an Outperform rating on the shares. The firm updated its model following mixed Ph 3 Sentry data which may still have a possible path forward in MF.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KPTI

Unlock Now

About KPTI

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Biotech Landscape Update: Regulatory Approvals and Mergers

3 days agoNASDAQ.COM

Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.

KPTI Shares Drop in Pre-Market Trading Despite Karyopharm's Myelofibrosis Treatment Achieving Key Goal — Retail Investors Skeptical of FDA Approval

6 days agostocktwits

Phase 3 Trial Results: Karyopharm's Phase 3 SENTRY trial showed that 50% of patients treated with selinexor combined with ruxolitinib achieved significant spleen volume reduction, compared to 28% with ruxolitinib alone, indicating promising efficacy for treating myelofibrosis.
Private Placement Announcement: Karyopharm announced a private placement deal with RA Capital Management to raise approximately $30 million, which is expected to support operations and planned clinical trials into the third quarter of 2026.
Stock Performance: Following the positive trial results, Karyopharm's stock initially gained but later reversed to a 13% decline in pre-market trading, reflecting mixed sentiment among investors regarding the FDA's potential approval of the drug.
Future Plans: The company plans to meet with the FDA to discuss next steps, including the possibility of filing a supplemental new drug application (sNDA) based on the trial data, which they believe could significantly improve clinical outcomes for patients.

Karyopharm Seeks Label Expansion for Xpovio After Positive Trial Results

Mar 24 2026seekingalpha

Clinical Trial Success: Karyopharm Therapeutics announced that its lead asset, selinexor, succeeded in a late-stage trial for myelofibrosis, with over 35% of patients showing significant spleen volume reduction, indicating treatment efficacy.
Safety Assessment: The SENTRY trial demonstrated that the combination of selinexor and JAK inhibitor ruxolitinib had a manageable safety and tolerability profile, although 15% of patients discontinued treatment due to adverse events, with no new safety signals identified.
FDA Meeting Plans: Karyopharm plans to meet with the FDA to discuss the trial results and anticipates filing a supplemental new drug application for selinexor in myelofibrosis, which could further advance its market entry.
Positive Stock Reaction: Following the announcement, Karyopharm's shares surged approximately 14%, and the company also revealed a $30 million private placement with RA Capital Management, enhancing its financial strength to support ongoing research and development.

Karyopharm Therapeutics Secures $30M Private Placement

Mar 24 2026seekingalpha

Funding Size: Karyopharm Therapeutics announced a $30 million private placement with RA Capital, with an additional ~$44 million expected if accompanying warrants are fully exercised, indicating strong market confidence in its future growth.
Share Sale Details: The private placement involves the sale of approximately 1.03 million shares at $6.785 each, along with about 3.39 million pre-funded warrants priced at $6.7849 each, providing substantial funding to support the company's clinical trial activities.
Use of Proceeds: The proceeds will be allocated for general corporate purposes, particularly to support ongoing and planned clinical trial activities, which will aid in advancing its research and development efforts and enhance market competitiveness.
Stock Price Reaction: Following the announcement of the private placement, Karyopharm's stock price jumped approximately 18% to $7.81 during pre-market trading on Tuesday, reflecting investor optimism regarding the company's future prospects.

Karyopharm Reports Significant Results from SENTRY Trial for Myelofibrosis

Mar 24 2026PRnewswire

Significant Efficacy: Karyopharm's SENTRY trial demonstrated that the combination of 60 mg selinexor with ruxolitinib significantly increased the proportion of patients achieving a spleen volume reduction of 35% or more, indicating important clinical relevance in treating myelofibrosis.
Survival Signal: The combination therapy showed a greater than 50% reduction in the risk of death at 24 weeks, suggesting its potential to improve overall survival rates for patients, which may provide new directions for future treatments.
Good Safety Profile: No new safety signals were identified in the combination treatment group, and the adverse event rates were consistent with the known safety profiles of selinexor and ruxolitinib used individually, indicating good tolerability.
Next Steps: Karyopharm plans to meet with the FDA to discuss the totality of the data and its supplemental new drug application, with expectations to submit relevant data in the second half of 2026 to further advance the clinical application of selinexor.